Harvard Bioscience (HBIO) Non-Current Assets (2010 - 2026)
Harvard Bioscience (HBIO) posted quarterly Non-Current Assets of $30.5 million for Q1 2026, down 12.72% year-over-year from $34.9 million in Q1 2025, and down 4.36% quarter-over-quarter from $31.8 million in Q4 2025.
Harvard Bioscience (HBIO) Non-Current Assets (2010 - 2026) Analysis & Trends
Harvard Bioscience (HBIO) has reported Non-Current Assets for 17 consecutive years, with $30.5 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Non-Current Assets fell 12.72% year-over-year to $30.5 million; the TTM figure through Mar 2026 stood at $131.6 million (down 53.55% YoY), while the FY2025 annual figure was $31.8 million, down 60.94% from the prior year.
- Non-Current Assets retreated to $30.5 million in Q1 2026 per HBIO's latest filing, from $31.8 million in the prior quarter.
- Across five years, Non-Current Assets topped out at $98.8 million in Q2 2022 and bottomed at $30.5 million in Q1 2026.
- Historically, Non-Current Assets has averaged $73.4 million across 5 years, with a median of $85.0 million in 2024.
- Annual changes were most pronounced in 2022 — Non-Current Assets dropped 1.63% — and 2025, when it plunged 60.94%.
- Harvard Bioscience's Non-Current Assets stood at $94.2 million in 2022, then fell by 6.27% to $88.3 million in 2023, then fell by 7.7% to $81.5 million in 2024, then slumped by 60.94% to $31.8 million in 2025, then dropped by 4.36% to $30.5 million in 2026.
- Business Quant data shows HBIO's Non-Current Assets at $30.5 million in Q1 2026, $31.8 million in Q4 2025, and $34.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Intuitive Surgical | 134.22 Bn | 129.00 Bn | 1.96 Bn | 11.33 Bn |
| 2 | Becton Dickinson | 52.42 Bn | 51.56 Bn | 2.32 Bn | 42.59 Bn |
| 3 | Alcon | 35.74 Bn | 34.39 Bn | 1.68 Bn | 24.47 Bn |
| 4 | Resmed | 33.89 Bn | 32.42 Bn | 861.22 Mn | 4.64 Bn |
| 5 | Medline | 28.89 Bn | 26.21 Bn | 2.22 Bn | 27.61 Bn |
| 6 | West Pharmaceutical Services | 25.07 Bn | 24.64 Bn | 329.20 Mn | 2.27 Bn |
| 7 | Solventum | 15.30 Bn | 14.90 Bn | 1.29 Bn | 10.50 Bn |
| 8 | Cooper Companies | 14.83 Bn | 14.69 Bn | 735.40 Mn | 10.18 Bn |
| 9 | Baxter International | 13.62 Bn | 11.47 Bn | 1.03 Bn | 12.80 Bn |
| 10 | Harvard Bioscience | 33.72 Mn | 27.22 Mn | 12.63 Mn | 29.82 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 29.82 Mn |
| Mar 31, 2026 | 30.46 Mn |
| Dec 31, 2025 | 31.85 Mn |
| Sep 30, 2025 | 34.19 Mn |
| Jun 30, 2025 | 35.12 Mn |
| Mar 31, 2025 | 34.90 Mn |
| Dec 31, 2024 | 81.53 Mn |
| Sep 30, 2024 | 84.45 Mn |
| Jun 30, 2024 | 82.48 Mn |
| Mar 31, 2024 | 85.01 Mn |
| Dec 31, 2023 | 88.33 Mn |
| Sep 30, 2023 | 89.25 Mn |
| Jun 30, 2023 | 90.28 Mn |
| Mar 31, 2023 | 93.13 Mn |
| Dec 31, 2022 | 94.24 Mn |
| Sep 30, 2022 | 95.20 Mn |
| Jun 30, 2022 | 98.78 Mn |
| Mar 31, 2022 | 98.60 Mn |
| Dec 31, 2021 | 100.76 Mn |
| Sep 30, 2021 | 98.19 Mn |